We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Read MoreHide Full Article
Insys Therapeutics, Inc. announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
The candidate is being evaluated for the treatment of cocaine dependence. The trial will determine the effects of CBD on the management of craving and withdrawal symptoms along with prevention of relapse, helping patients in both the initial stages of treatment and long-term commitment to remission of addiction.
The phase II study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM), and is supported by the Canadian Institutes of Health Research (CIHR) as well as Insys.
According to the company’s press release, cocaine addiction leads to over 500,000 emergency room visits per year and more than 5,000 deaths, resulting in significant financial and social burden related to crime, loss of productivity and healthcare costs.
We note that Insys currently markets Subsys, a fentanyl sublingual spray approved for the treatment of breakthrough cancer pain in opioid-tolerant patients.
The company recently received marketing approval for Syndros, an administered liquid formulation of dronabinol.
Another biopharmaceutical company, GW Pharmaceuticals plc is also developing therapeutics from its proprietary cannabinoid product platform for the treatment of a broad range of diseases. The company has Sativex in its portfolio, the world’s first plant-derived cannabinoid prescription drug approved for the treatment of spasticity due to multiple sclerosis.
Insys Therapeutics currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Insys Therapeutics, Inc. announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
The candidate is being evaluated for the treatment of cocaine dependence. The trial will determine the effects of CBD on the management of craving and withdrawal symptoms along with prevention of relapse, helping patients in both the initial stages of treatment and long-term commitment to remission of addiction.
The phase II study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM), and is supported by the Canadian Institutes of Health Research (CIHR) as well as Insys.
According to the company’s press release, cocaine addiction leads to over 500,000 emergency room visits per year and more than 5,000 deaths, resulting in significant financial and social burden related to crime, loss of productivity and healthcare costs.
We note that Insys currently markets Subsys, a fentanyl sublingual spray approved for the treatment of breakthrough cancer pain in opioid-tolerant patients.
The company recently received marketing approval for Syndros, an administered liquid formulation of dronabinol.
Another biopharmaceutical company, GW Pharmaceuticals plc is also developing therapeutics from its proprietary cannabinoid product platform for the treatment of a broad range of diseases. The company has Sativex in its portfolio, the world’s first plant-derived cannabinoid prescription drug approved for the treatment of spasticity due to multiple sclerosis.
Insys Therapeutics currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>